US health regulator finds Silvassa unit non-compliant with CGMP: Ipca Labs

The company said that since this manufacturing facility is already under USFDA import alert and presently not doing any US business, this will have no impact on company's current on-going business activities. The USFDA inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news